GlassScriptPhysician profile
Daryl A Perlman
NPI 1538116900
$2,622.70
in general payments reported to CMS, 2019-2025
31 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $42.10 · 2021: $308 · 2022: $304 · 2023: $381 · 2024: $278 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.14 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $375.36 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Vivus LLC | $370.47 | 2019-2025 | Qsymia |
| Novo Nordisk INC | $210.05 | 2019-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $165.21 | 2019 | |
| Insulet Corporation | $157.34 | 2021-2022 | |
| Eisai INC. | $154.35 | 2019 | |
| Intuity Medical INC | $121.24 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Intra-Sana Laboratories | $98.44 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Currax Pharmaceuticals LLC | $83.61 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Amarin Pharma, INC. | $81.94 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $75.04 | 2019 | |
| Mannkind Corporation | $74.33 | 2019-2023 | Afrezza |
| Amgen INC. | $70.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.84 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $66.23 | 2022-2025 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $47.09 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $45.24 | 2022-2025 | |
| Beta Bionics, INC. | $42.60 | 2024 | Ilet Bionic Pancreas |
| Cequr Corporation | $39.00 | 2023-2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $33.00 | 2019 | |
| Endo Pharmaceuticals INC. | $32.45 | 2019-2020 | |
| Antares Pharma, INC. | $31.14 | 2025 | Xyosted |
| Madrigal Pharmaceuticals | $28.54 | 2025 | Rezdiffra |
| Abbott Laboratories | $25.52 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $21.34 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $20.50 | 2025 | Arexvy, Shingrix |
| Verity Pharmaceuticals INC. | $19.46 | 2025 | Tlando |
| Zealand Pharma US, INC. | $19.12 | 2021 | |
| Corcept Therapeutics | $17.33 | 2022 | |
| Clarus Therapeutics INC. | $15.12 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Perlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.